we provide the evidence that down-regulation of miR-18a sensitizes non-small-cell lung cancer to radiation treatment

Reduced miR18a expression is associated with non-small cell lung cancer.

Patients with non-small cell lung cancer (NSCLC) and high plasma expression levels of miR-18a, miR-20a, and miR-92a as well as lymphatic node metastasis had a shorter overall survival than patients with low expression levels of these miRNAs. Thus, the circulating miR-18a, miR-20a, and miR-92a levels may serve as novel and promising prognostic biomarkers in patients with NSCLC.

these results indicate that miR-18a-5p increases the radiosensitivity in lung cancer cells and CD133(+) stem-like cells via downregulating ATM and HIF-1alpha expressions. Plasma miR-18a-5p would be an available indicator of radiosensitivity in lung cancer patients.

ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.